Literature DB >> 21452186

Role of endonucleases XPF and XPG in nucleotide excision repair of platinated DNA and cisplatin/oxaliplatin cytotoxicity.

Nora Graf1, Wee Han Ang, Guangyu Zhu, MyatNoeZin Myint, Stephen J Lippard.   

Abstract

Resistance of tumor cells to platinum anticancer agents poses a major problem in cancer chemotherapy. One of the mechanisms associated with platinum-based drug resistance is the enhanced capacity of the cell to carry out nucleotide excision repair (NER) on platinum-damaged DNA. Endonucleases XPF and XPG are critical components of NER, responsible for excising the damaged DNA strand to remove the DNA lesion. Here, we investigated possible consequences of down-regulation of XPF and XPG gene expression in osteosarcoma cancer cells (U2OS) and the impact on cellular transcription and DNA repair. We further evaluated the sensitivity of such cells toward the platinum anticancer drugs cisplatin and oxaliplatin.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21452186      PMCID: PMC3081389          DOI: 10.1002/cbic.201000724

Source DB:  PubMed          Journal:  Chembiochem        ISSN: 1439-4227            Impact factor:   3.164


  51 in total

1.  Translesion synthesis of 1,3-GTG cisplatin DNA lesions.

Authors:  Sabine Schneider; Thomas Reissner; Omer Ziv; Zvi Livneh; Thomas Carell
Journal:  Chembiochem       Date:  2010-07-26       Impact factor: 3.164

2.  Mechanism of transcriptional stalling at cisplatin-damaged DNA.

Authors:  Gerke E Damsma; Aaron Alt; Florian Brueckner; Thomas Carell; Patrick Cramer
Journal:  Nat Struct Mol Biol       Date:  2007-11-11       Impact factor: 15.369

Review 3.  Molecular mechanisms of mammalian global genome nucleotide excision repair.

Authors:  Ludovic C J Gillet; Orlando D Schärer
Journal:  Chem Rev       Date:  2006-02       Impact factor: 60.622

4.  The XPA-binding domain of ERCC1 is required for nucleotide excision repair but not other DNA repair pathways.

Authors:  Barbara Orelli; T Brooke McClendon; Oleg V Tsodikov; Tom Ellenberger; Laura J Niedernhofer; Orlando D Schärer
Journal:  J Biol Chem       Date:  2009-11-23       Impact factor: 5.157

5.  Expression of genes involved in nucleotide excision repair and sensitivity to cisplatin and melphalan in human cancer cell lines.

Authors:  G Damia; G Guidi; M D'Incalci
Journal:  Eur J Cancer       Date:  1998-10       Impact factor: 9.162

Review 6.  How nucleotide excision repair protects against cancer.

Authors:  E C Friedberg
Journal:  Nat Rev Cancer       Date:  2001-10       Impact factor: 60.716

7.  Reaction mechanism of human DNA repair excision nuclease.

Authors:  D Mu; D S Hsu; A Sancar
Journal:  J Biol Chem       Date:  1996-04-05       Impact factor: 5.157

8.  RNA polymerase II blockage by cisplatin-damaged DNA. Stability and polyubiquitylation of stalled polymerase.

Authors:  Yongwon Jung; Stephen J Lippard
Journal:  J Biol Chem       Date:  2005-11-07       Impact factor: 5.157

9.  Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts.

Authors:  J T Reardon; A Vaisman; S G Chaney; A Sancar
Journal:  Cancer Res       Date:  1999-08-15       Impact factor: 12.701

Review 10.  Nucleotide excision repair and cancer.

Authors:  Diana Leibeling; Petra Laspe; Steffen Emmert
Journal:  J Mol Histol       Date:  2006-07-20       Impact factor: 3.156

View more
  17 in total

Review 1.  DNA repair pathways and their roles in drug resistance for lung adenocarcinoma.

Authors:  Altan Kara; Aykut Özgür; Sinem Nalbantoğlu; Abdullah Karadağ
Journal:  Mol Biol Rep       Date:  2021-04-15       Impact factor: 2.316

2.  Chemoresistant lung cancer stem cells display high DNA repair capability to remove cisplatin-induced DNA damage.

Authors:  Wai-Kin Yu; Zhigang Wang; Chi-Chun Fong; Dandan Liu; Tak-Chun Yip; Siu-Kie Au; Guangyu Zhu; Mengsu Yang
Journal:  Br J Pharmacol       Date:  2017-01-16       Impact factor: 8.739

3.  XRCC1 and XPD genetic polymorphisms and clinical outcomes of gastric cancer patients treated with oxaliplatin-based chemotherapy: a meta-analysis.

Authors:  Xin Zhang; Li-Peng Jiang; Yu Yin; Ya-Di Wang
Journal:  Tumour Biol       Date:  2014-03-04

4.  Monofunctional platinum-DNA adducts are strong inhibitors of transcription and substrates for nucleotide excision repair in live mammalian cells.

Authors:  Guangyu Zhu; MyatNoeZin Myint; Wee Han Ang; Lina Song; Stephen J Lippard
Journal:  Cancer Res       Date:  2011-12-16       Impact factor: 12.701

Review 5.  The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.

Authors:  Timothy C Johnstone; Kogularamanan Suntharalingam; Stephen J Lippard
Journal:  Chem Rev       Date:  2016-02-11       Impact factor: 60.622

6.  Platinum(IV)-chlorotoxin (CTX) conjugates for targeting cancer cells.

Authors:  Nora Graf; Tara E Mokhtari; Ioannis A Papayannopoulos; Stephen J Lippard
Journal:  J Inorg Biochem       Date:  2012-02-23       Impact factor: 4.155

7.  Expression of XPG protein in human normal and tumor tissues.

Authors:  Miguel Aracil; Lisa M Dauffenbach; Marta Martínez Diez; Rana Richeh; Victoria Moneo; Juan Fernando Martínez Leal; Luis Francisco García Fernández; Christopher A Kerfoot; Carlos M Galmarini
Journal:  Int J Clin Exp Pathol       Date:  2013-01-15

8.  Using Molecular Markers to Guide Therapy of Metastatic Colorectal Cancer.

Authors:  Autumn McRee; Bert H O'Neil
Journal:  J Oncopathol       Date:  2013-09-01

9.  SLX4IP acts with SLX4 and XPF-ERCC1 to promote interstrand crosslink repair.

Authors:  Huimin Zhang; Zhen Chen; Yin Ye; Zu Ye; Dan Cao; Yun Xiong; Mrinal Srivastava; Xu Feng; Mengfan Tang; Chao Wang; John A Tainer; Junjie Chen
Journal:  Nucleic Acids Res       Date:  2019-11-04       Impact factor: 16.971

10.  XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: suitability as a biomarker for patient selection.

Authors:  Stephanie B Hatch; Lonnie P Swift; Simona Caporali; Rebecca Carter; Esme J Hill; Thomas P MacGregor; Stefania D'Atri; Mark R Middleton; Peter J McHugh; Ricky A Sharma
Journal:  Int J Cancer       Date:  2013-11-14       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.